PT-141 Research Overview (also known as Bremelanotide, Vyleesi)
A cyclic heptapeptide melanocortin receptor agonist studied for its influence on sexual arousal and libido in both male and female research models. Acts centrally through melanocortin receptors in the brain. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
What Is PT-141?
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II — specifically engineered to retain the pro-sexual MC4R activation while eliminating the melanogenic and blood pressure-raising effects of its parent compound. It was approved by the FDA in June 2019 (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first and currently only melanocortin-pathway drug approved for sexual dysfunction.
Central Mechanism of Action
PT-141 works through an entirely different mechanism from phosphodiesterase inhibitors. Rather than acting on penile or vaginal vasculature, it activates MC4R and MC3R receptors in hypothalamic regions governing sexual motivation and arousal. This increases central dopaminergic signaling through melanocortin pathways, creating neurological arousal followed by peripheral physiological responses. This central mechanism means PT-141 can address psychogenic sexual dysfunction that peripherally-acting drugs cannot reach.
Male Applications and Administration
Though approved only for female HSDD, PT-141 has been extensively studied in men with erectile dysfunction — including men who fail to respond to sildenafil — with significant improvements in erectile function documented. It is approved as a subcutaneous injection taken 45 minutes before anticipated sexual activity.
Quick Reference
| Literature-Reported Dose Range | 1.75mg for women, 1-2mg for men |
| Literature-Reported Frequency | As needed, 45-60 minutes before sexual activity |
| Literature-Reported Cycle Length | No cycling needed - use as required |
| Literature-Reported Washout | Minimum 24 hours between doses |
| Storage | Refrigerate reconstituted solution (2-8°C), use within 30 days |
| Sites Reported in Studies | Subcutaneous: abdomen (2 inches from navel) or upper thigh |
| Timing | 45-60 minutes before anticipated sexual activity |
Research Indications
Hormonal
Hypoactive Sexual Desire Disorder (HSDD)
FDA-approved for premenopausal women with acquired, generalized HSDD
Erectile Dysfunction
Effective in men including those unresponsive to PDE5 inhibitors
Female Sexual Arousal Disorder
Improves physiological and subjective arousal measures
Mood
Reduced Sexual Distress
Clinical trials show significant reduction in distress related to low sexual desire
Enhanced Sexual Satisfaction
Improvements in overall sexual satisfaction scores in both partners
Psychological Well-being
Positive effects on relationship satisfaction and quality of life
Metabolic
Metabolic Neutral
No significant effects on glucose metabolism unlike some melanocortin agonists
Weight Neutral
Unlike Melanotan II, minimal effects on appetite or weight
Cardiovascular Safety
Extensive safety data shows manageable cardiovascular profile
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Female HSDD (FDA-approved) | 1.75mg | As needed, max 1 dose/24hr | SubQ (abdomen/thigh) |
| Male Erectile Dysfunction | 1-2mg | As needed, 45-60min before activity | SubQ |
| Female Arousal Disorder | 0.75-1.25mg | As needed, max 1 dose/24hr | SubQ |
| Low Starting Dose | 0.5mg | Test dose to assess tolerance | SubQ |
Timing
Recommended administration window: 45-60 minutes before anticipated sexual activity. Typical onset: onset 45-60min, peak effects 2-4 hours, duration 6-12 hours.
Peptide Interactions
Can be used together but monitor for additive blood pressure effects. PT-141 works centrally while PDE5 inhibitors work peripherally.
Both are melanocortin agonists - combining may lead to excessive melanocortin activation and side effects. Not recommended without medical supervision.
PT-141 can transiently lower blood pressure. Monitor BP closely when combining with antihypertensives.
Both can lower blood pressure and cause flushing. Limit alcohol intake when using PT-141 to avoid excessive hypotension.
Risk of severe hypotension. Do not use PT-141 with nitrate medications for heart conditions.
No known interactions. Different mechanisms of action - PT-141 for sexual function, BPC-157 for tissue repair.
May work synergistically for sexual dysfunction. PT-141 addresses arousal while testosterone supports libido and function.
Both affect sexual function through different pathways - PT-141 via melanocortin receptors (MC3R/MC4R), Kisspeptin via GnRH stimulation. No receptor overlap but monitor for additive effects on blood pressure and hormonal response.
Reported Research Timeline
01First 30–45 minutes (reported in cited studies): may experience mild nausea or facial flushing
0245-90 minutes: Onset of effects - increased arousal and desire
032-4 hours: Peak effects - enhanced sexual response and satisfaction
046-12 hours: Effects gradually diminish
05Long-term (reported in cited studies): no tolerance development reported with intermittent use
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Common side effects: nausea (40%), flushing (20%), headache (11%)
Take anti-nausea medication 30 minutes before if prone to nausea
Monitor blood pressure - can cause transient decrease
Not for use with uncontrolled hypertension or cardiovascular disease
Avoid alcohol to minimize blood pressure effects
FDA black box warning for blood pressure effects
Seek Medical Attention If:
Severe or persistent nausea/vomiting
Significant drop in blood pressure or dizziness
Chest pain or irregular heartbeat
Severe headache or vision changes
Prolonged erection (>4 hours) - rare but seek immediate medical attention
Severe skin darkening (rare with PT-141 vs other melanocortins)
Quality Indicators
Verified Marker
FDA-approved pharmaceutical grade
If prescribed as Vyleesi, guaranteed pharmaceutical quality and safety
Verified Marker
White crystalline powder
Pure PT-141 appears as white to off-white lyophilized powder
Verified Marker
Clear solution when reconstituted
Properly manufactured PT-141 dissolves completely without cloudiness
Quality Concern
Colored or oily appearance
May indicate impurities or degradation - do not use
Acceptable Range
Compounded versions
Ensure compounding pharmacy is licensed and follows USP standards
Verified Marker
Proper labeling with concentration
Legitimate sources provide clear concentration and purity information
Research Citations
- FDA Approval Trial for Hypoactive Sexual Desire Disorder (2019)
Human | 1.75mg subcutaneous | As needed | 24.5% improvement vs 17.2% placebo - Male Erectile Dysfunction Clinical Trial (2017)
Human | 1-20mg intranasal | Single dose | Dose-dependent erectile response - Mechanism of Action Study (2016)
In vitro + Animal | Various doses | Receptor binding assays - Female Sexual Arousal Disorder Trial (2013)
Human | 0.75-1.25mg subcutaneous | Single dose | Improved arousal metrics - Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L, 2026, Int J Mol Sci - Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization
Hadley ME, Dorr RT, 2006, Peptides - Melanocortins in the treatment of male and female sexual dysfunction
Shadiack AM, Sharma SD, Earle DC, 2007, Curr Top Med Chem - Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions
Ila V, Pozzi E, Gamage M, 2025, Expert Opin Pharmacother
Research Focus
Sexual dysfunction, Erectile dysfunction, Female sexual arousal, MC4R agonism, Libido
Verified Vendors Carrying PT-141
Frequently Asked Questions
What should researchers watch for with PT-141?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with PT-141?
First 30–45 minutes (reported in cited studies): may experience mild nausea or facial flushing
How is PT-141 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →